BusinessSummit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDBy Nasdaq OMXNov 16, 2016, 12:00 PM UTC
BusinessSummit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle SocietyBy Nasdaq OMXOct 6, 2016, 11:00 AM UTC
BusinessSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:02 AM UTC
BusinessSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:00 AM UTC
BusinessSummit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessSummit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy CommunityBy Nasdaq OMXSep 12, 2016, 11:00 AM UTC
BusinessFDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)By Nasdaq OMXSep 7, 2016, 12:00 PM UTC
BusinessSummit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceBy Nasdaq OMXSep 7, 2016, 11:00 AM UTC
